Physician profile
Helen Lu
NPI 1174987788
$1,289.68
in general payments reported to CMS, 2019-2025
13 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.11 · 2022: $158 · 2023: $271 · 2024: $679 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $313.43 | 2024 | Fruzaqla |
| Bayer Healthcare Pharmaceuticals INC. | $172.87 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.98 | 2022-2023 | Jardiance |
| Jazz Pharmaceuticals INC. | $142.78 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $139.48 | 2022 | |
| Emd Serono, INC. | $124.98 | 2024 | |
| Pfizer INC. | $86.42 | 2025 | |
| Eisai INC. | $43.11 | 2024-2025 | |
| Genentech USA, INC. | $34.97 | 2025 | Venclexta |
| Tersera Therapeutics LLC | $30.58 | 2024 | Xermelo |
| Glaxosmithkline, LLC. | $29.99 | 2025 | Ojjaara, Blenrep |
| Alexion Pharmaceuticals, INC. | $15.98 | 2024 | Ultomiris |
| Abbvie INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.